Scarica l'app Stockscreener
2.06
1.44%
-0.03
Dopo l'orario di chiusura:
2.06
Precedente Chiudi:
$2.09
Aprire:
$2.07
Volume 24 ore:
26,724
Relative Volume:
0.41
Capitalizzazione di mercato:
$16.98M
Reddito:
$2.00M
Utile/perdita netta:
$-11.43M
Rapporto P/E:
-1.0526
EPS:
-1.957
Flusso di cassa netto:
$-10.05M
1 W Prestazione:
+0.49%
1M Prestazione:
-0.96%
6M Prestazione:
-78.15%
1 anno Prestazione:
-33.76%
Intervallo 1D:
$2.0501
$2.10
Intervallo di 1 settimana:
$2.04
$2.1349
Portata 52W:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Nome
Lipocine Inc
Settore
Industria
Telefono
801 994 7383
Indirizzo
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.06 | 17.23M | 2.00M | -11.43M | -10.05M | -1.957 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-06-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-11 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
| 2015-06-23 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Lipocine Inc Borsa (LPCN) Ultime notizie
Lipocine (LPCN) adds Grissinger to pay panel at $7,500 a year - Stock Titan
Lipocine (LPCN) Q2 2026 Scorecard: EPS Comes in Above Forecast in Latest Trading; Price Reaction - vinanet.vn
Lipocine (LPCN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations in Latest Trading; Immediate Response: The Stock Ends Down 0.49% in the Current UpdateEarnings Preview - dars.gov.et
Lipocine Stock Price Forecast. Should You Buy LPCN? - StockInvest.us
Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake - Stock Titan
LPCN Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Revenue Remains Absent - Vinanet
Weekly Recap: Q2 revenue drop and Brilzio partner search - TradingView
LPCN Q2 2026 Earnings: Loss Narrower Than Expected, Shares Ease 1.41%Earnings Turnaround - vinanet.vn
Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options - Stock Titan
Lipocine Inc. (LPCN) director Grissinger files initial ownership statement - Stock Titan
Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Lipocine files Form 3 initial beneficial ownership statement for director Michael Grissinger - Bitget
Lipocine Inc (LPCN) Stock News Today - TradingKey
Lipocine (LPCN) Stock Analysis: Flat at $2.13, What's Next 2026-08-07Zero Lag EMA - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Lipocine (LPCN) and High Tide (HITI) - The Globe and Mail
Lipocine (LPCN) Slips 1.8% to $2.13 as Biotech Stock Holds Above Key $2.02 SupportETF Flow - vinanet.vn
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lipocine Q2 2026 earnings: Missing license revenue drives top-line decline - TradingKey
Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates - Kalkine
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 - Morningstar
Lipocine Q2 net loss widens as revenue declines - TradingView
Lipocine posts $2.6 million Q2 net loss as revenue falls - Quiver Quantitative
Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary - TradingView
Lipocine (NASDAQ: LPCN) widens H1 loss but extends cash runway to 2027 - stocktitan.net
Lipocine: Q2 Earnings Snapshot - AOL.com
Lipocine Appoints Michael J. Grissinger to Board of Directors - Morningstar
Lipocine Appoints Industry Veteran Grissinger to Board - TipRanks
Lipocine appoints Michael Grissinger to board of directors By Investing.com - Investing.com Australia
Lipocine appoints Michael Grissinger to board of directors - Investing.com India
Lipocine Inc. Announces Appointment of Michael J. Grissinger to Board of Directors, Effective August 3, 2026 - marketscreener.com
Lipocine Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Lipocine Inc (LPCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LPCN|Lipocine Inc|Price:2.160|Chg%:+0.080 - TradingKey
Lipocine Inc (LPCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lipocine Inc (LPCN) Income Statement - TradingKey
Lipocine Inc (LPCN) Balance Sheet - TradingKey
Lipocine Inc (LPCN) Cash Flow - TradingKey
Lipocine Inc. (LPCN) Q1 2026 Earnings: EPS Miss Pressures Shares as Pipeline Progress Remains KeyCost Structure Review - Vinanet
LPCN|Lipocine Inc|Price:2.080|Chg%:-0.110 - TradingKey
Lipocine Inc (LPCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lipocine Inc (LPCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lipocine Market Sentiment - Benzinga España
LPCN|Lipocine Inc|Price:2.210|Chg%:-0.020 - TradingKey
Lipocine Q1 2026 Earnings: Losses Slightly Wider Than Expected on No RevenueEPS Growth Report - dars.gov.et
LPCN Q1 2026 Earnings: Larger-than-Anticipated Loss as Development Spending ContinuesEPS Growth Rate - vinanet.vn
Lipocine (LPCN) Faces Slight Pullback Amid Sector VolatilityBear Pennant - dars.gov.et
Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in FocusBull Pennant - dars.gov.et
Lipocine Inc. (LPCN) Approaches Key Support After 2.85% Decline – Technical Levels in FocusFibonacci Arc - dars.gov.et
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss Drags Shares LowerHealthcare Earnings Report - dars.gov.et
Form 4 Lipocine Inc For: 30 June By Investing.com - Investing.com Canada
Lipocine Inc Azioni (LPCN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):